Nagoya Protocol (2010) — Treaty Brief

Overview

The Nagoya Protocol on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits Arising from their Utilization (2010) is a supplementary agreement to the Convention on Biological Diversity (CBD). It establishes a legal framework to ensure that benefits derived from the use of genetic resources, such as plants, animals, and microorganisms, are shared fairly and equitably with the countries and indigenous communities providing those resources. The Protocol aims to promote biodiversity conservation and sustainable use by creating transparent procedures for access to genetic resources and associated traditional knowledge, while respecting the sovereign rights of states over their natural resources.

Key Obligations

• Access to Genetic Resources: Parties must establish clear domestic measures to regulate access to genetic resources within their jurisdiction, requiring prior informed consent (PIC) from the providing country or indigenous communities before access is granted (Article 6).
• Benefit-Sharing: Users of genetic resources must share benefits arising from their utilization in a fair and equitable manner, through monetary or non-monetary benefits, as agreed upon mutually (Article 5).
• Traditional Knowledge: Parties must take measures to ensure that traditional knowledge associated with genetic resources, held by indigenous and local communities, is accessed with their prior informed consent and that benefits are shared fairly (Article 7).
• Compliance and Monitoring: Parties are required to monitor the utilization of genetic resources and ensure compliance with domestic access and benefit-sharing (ABS) laws, including through checkpoints such as research funding, patent applications, or commercialization processes (Articles 15 and 17).
• Mutually Agreed Terms (MAT): Access and benefit-sharing arrangements must be based on mutually agreed terms between providers and users (Article 5).
• National Focal Points and Competent National Authorities: Each Party must designate authorities responsible for granting access and facilitating benefit-sharing (Article 12).
• Information Sharing: Parties must make publicly available information on their ABS frameworks and provide access to relevant databases (Article 14).

Signatories and Status

The Nagoya Protocol has attracted broad international support, with most parties to the CBD also becoming parties to the Protocol. Major biodiversity-rich countries such as Brazil, India, South Africa, and members of the European Union have ratified the Protocol, reflecting their interest in protecting genetic resources and traditional knowledge. The European Union itself is a party, and its member states implement the Protocol through EU-wide regulations.

Notably, some major genetic resource users, including the United States, have not ratified the Protocol. The U.S. has signed the CBD itself but has not ratified it or the Nagoya Protocol, citing concerns over sovereignty and potential impacts on research and innovation. Similarly, other technologically advanced countries have hesitated or delayed ratification due to concerns about regulatory burdens and legal uncertainties.

Ratification patterns generally reflect a divide between provider countries, often biodiversity-rich developing states eager to assert control over genetic resources, and user countries, typically developed states with large biotechnology sectors concerned about access restrictions.

Major Controversies

• Interpretation of Prior Informed Consent and Mutually Agreed Terms: Disputes have arisen over what constitutes adequate prior informed consent, especially when indigenous communities are involved, and how mutually agreed terms should be negotiated and enforced. Some argue that overly stringent PIC requirements could hinder scientific research and innovation.
• Scope of Genetic Resources and Digital Sequence Information (DSI): A major ongoing controversy is whether the Protocol’s benefit-sharing obligations extend to digital sequence information derived from genetic resources. Many provider countries advocate for including DSI to prevent “biopiracy,” while user countries and researchers warn that this could complicate open data sharing essential for scientific progress.
• Enforcement and Compliance Gaps: Despite provisions for checkpoints and monitoring, enforcement remains uneven. Some countries lack the capacity to implement ABS measures effectively, leading to concerns about “biopiracy” and unauthorized use of genetic resources.
• Withdrawal and Non-Participation: Although no major withdrawals have occurred, the absence of key countries like the United States limits the Protocol’s global reach and complicates international cooperation.
• Impact on Research and Innovation: Critics argue that the Protocol’s regulatory framework can create legal uncertainty and administrative burdens for researchers and companies, potentially slowing innovation and access to genetic resources for non-commercial scientific purposes.

Recent Developments

In the last five years, negotiations under the CBD’s Conference of the Parties (COP) have increasingly focused on resolving the controversy over digital sequence information (DSI), with discussions ongoing about establishing new benefit-sharing mechanisms that do not impede open scientific data sharing. The 2020s have also seen efforts to improve capacity-building and technical assistance for developing countries to implement ABS frameworks effectively.

Several countries and regional blocs have updated or refined their domestic ABS legislation to better align with the Protocol’s requirements, aiming to clarify procedures and improve compliance. The European Union, for example, has advanced its ABS Regulation to strengthen implementation across member states.

Additionally, the COVID-19 pandemic highlighted the importance of genetic resource sharing for global health, renewing debates on equitable access and benefit-sharing in the context of pathogens and vaccines, although the Nagoya Protocol’s direct applicability to pathogens remains contested.

Why It Matters Now

The Nagoya Protocol remains a critical instrument for balancing biodiversity conservation, indigenous rights, and global scientific collaboration amid accelerating biotechnological advances. As genetic resource utilization expands in areas like synthetic biology and digital genomics, clarifying and updating ABS frameworks under the Protocol is essential to ensure fair benefit-sharing without stifling innovation. Its relevance is also heightened by growing global commitments to biodiversity protection and sustainable development goals.